

Flixene Vascular Graft

The right graft for AV access



Clinical Practice Guidelines for Vascular Access

KDOQI Guidelines



The latest KDOQI guidelines for dialysis care encourage "Attainment of the 'right access, in the right patient, at the right time, for the right reasons."


KDOQI considers it reasonable to have an AV access (AVF or AVG) in a patient requiring HD, when consistent with their ESKD Life-Plan and overall goals of care.¹³

ESVS Guidelines esvs



The European Society for Vascular Surgery (ESVS) 2018 guidelines on dialysis access emphasize a fistula-first approach. Prosthetic arteriovenous grafts (AVGs) are considered the secondary option when a fistula is not feasible, and central venous catheters (CVCs) are a last-resort tertiary option.¹⁴

While fistulas are preferred in general, the guidelines identify specific scenarios where a prosthetic AV graft is indicated or advantageous over a new fistula. This includes situations such as: no suitable autologous vessel for an AVF, elderly patients with high fistula failure risk, urgent or early dialysis need, failed prior access, and other anatomical challenges.



Designed for getting it right.



The right graft for long-lasting durability and proven reliability

- 3 layer graft comprised of ePTFE1, designed for repeated needle cannulation related to dialysis care2
- Key studies have demonstrated secondary patency rates greater than 83% at 12 months. 34.5.67
- The secondary patency rate was **77.7% at five years** (as reported by He et al.)⁷

3-Layer ePTFE graft Large pore (nominal 60pm) surface layer, more receptive to tissue in-growth⁸ Middle layer, reinforcing wrap for increased support⁹ Small pore (nominal 20pm) base layer inner graft surface porosity¹⁰



The right graft for safe graft placement

- Low-profile Graft Deployment System (GDS), designed to make tunneling easier than conventional practices¹¹
- Improved primary patency at 180 days (as reported by Schild et al.)11
- Minimized soft tissue trauma and reduced graft sweating (as reported by Schild et al.)11



Why Flixene stands out.



The right graft for suturability and handling

- Reduced wall thickness (~8cm) on each end²
- Unique graduated wall design for ease of suturing²
- Tapered configuration designed to change flow dynamics12






The right graft for early cannulation

- On-label for 24 hour access1
- Demonstrated as a safe and effective early cannulation option^{5,7}
- An alternative to central venous catheters^{5,7}



Product information

Flixene Vascular Graft





Vascular Graft Tunneler Instrumentation

Tunneler Rod

Product	Description	Reference
AV-1, vascular graft tunneler rod	26 cm length with 50° curve (stainless steel)	26012
AV-2, vascular graft tunneler rod	27 cm length with 180° curve (stainless steel)	26013
PV-1, vascular graft tunneler rod	33cm length with 12° curve (stainless steel)	26014
PV-2, vascular graft tunneler rod	58 cm length with 24° curve (stainless steel)	26015

Tunneler Tip

Product	Description	Reference
Vascular graft tunneler tips (4 mm)	Set of 2	26018
Vascular graft tunneler tips (5 mm)	Set of 2	26019
Vascular graft tunneler tips (6 mm)	Set of 2	26007
Vascular graft tunneler tips (7 mm)	Set of 2	26008
Vascular graft tunneler tips (8 mm)	Set of 2	26009
Vascular graft tunneler tips (10 mm)	Set of 2	26010
Set of 8 size vascular graft tunneler tips	2 per size: 6 mm, 7 mm, 8 mm, 10 mm	26006

References

- 1. Data on file
- 2. Data on file
- 3. Chemla ES, Nelson S, Morsy M. Early cannulation grafts in straight axillo-axillary angio accesses avoid central catheter insertions. Semin Dial. 2011;24:456-459. doi: 10.1111/j.1525-139X.2011.00918.x
- 4. Scarritt T, Paragone CM, O'Gorman RB, et al. Traditional versus early-access grafts for hemodialysis access: a single-institution comparative study. Am Surg. 2014;80:155-158.
- 5. Berard X, Ottaviani N, Brizzi V, et al. Use of the Flixene vascular access graft as an early cannulation solution. J Vasc Surg. 2015;62:128-134. doi: 10.1016/j.jvs.2015.02.002
- 6. Sutaria R, Gilbert JA. Single-centre experience of an early cannulation graft for haemodialysis access. J Vasc Access. Published online March 6, 2020. doi: 10.1177/1129729820909026
- 7. He B, Tailor D, Ng ZQ, Samuelson S, Nadkarni S, Van Myk M, Ferguson J, Tibballs J, Chan D. Long-Term Outcomes of the Flixene Vascular Graft Used for Haemodialysis. Cureus. 2021
- 8. Data on file
- 9. Data on file
- 10. Data on file
- 11. Schild et al, New graft for low friction tunneling in vascular access surgery, The Journal of Vascular Access 2004; 5: 19-24
- 12. Data on file
- 13. Lok, Charmaine et al; KDOQI Clinical Practice Guidelines for Vascular Access: 2019 Update
- 14. Schmidli, Jurg et al; Editor's Choice -- Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS)



Refer to Instructions For Use for current indications, warnings, contraindications, and precautions. This information is aimed exclusively at healthcare professionals or other professional audiences and is for informational purposes only, is not exhaustive and therefore should not be relied upon as a replacement of the Instructions for Use, service manual or medical advice. Getinge shall bear no responsibility or liability for any action or omission of any party based upon this material, and reliance is solely at the user's risk.

Any therapy, solution or product mentioned might not be available or allowed in your country. Information may not be copied or used, in whole or in part, without written permission by Getinge.

Product might not be available in all countries; please check with your local Getinge sales team. Getinge reserves the right to make changes in specifications and / or to discontinue any products at any time without notice or obligation and will not be liable for any consequences resulting from the use of this publication.

This information is intended for a global audience.

Slider graft deployment system (GDS), Vascular tunneler, and FLIXENE vascular grafts are manufactured by Atrium Medical Corporation / 40 Continental Blvd., Merrimack, NH 03054 / Tel. 603-880-1433 · Protected by the following international and U.S. patent(s): http://patents.maquet.com. Getinge and Atrium are trademarks or registered trademarks of Getinge AB, its subsidiaries or affiliates in the United States or other countries · Getinge and Atrium are registered with the US Patent and Trademark Office. · Copyright 2025 Getinge or its affiliates. · All rights not expressly granted are reserved. · Printed in U.S.A. · 09/2025

Atrium Medical Corporation · 40 Continental Blvd. · Merrimack, NH 03054 · USA · (603) 880-1433 **www.getinge.com**